title: The effect of migraine prophylaxis on migraine-related resource use and productivity.
abstract: In the US, it is estimated that up to 10% of men and 25% of women, particularly those aged 25-55 years, experience debilitating migraines, such that the condition presents an enormous economic burden for patients, health systems, employers and society. Migraine headache is a particularly prevalent condition associated with major reductions in patients' quality of life. From a payer perspective, the implementation of relevant programmes of migraine prophylaxis is highly desirable. Consistent evidence exists, from several randomized, controlled studies, of the efficacy of amitriptyline, divalproex sodium, propranolol, timolol and topiramate in migraine prophylaxis. Considering resource utilization, various studies suggest that migraine prophylaxis with antiepileptics, antidepressants, beta-blockers or calcium channel antagonists markedly reduces triptan use and visits to physician offices and emergency departments (EDs), without compromising quality of care or treatment outcomes. Over recent years, the effects of topiramate in reducing resource utilization in patients with migraine have been relatively widely studied. In US claims database analyses involving >4000 patients with migraine, topiramate significantly reduced triptan use by up to 20% in the 12-month period after starting treatment. Reductions were also noted in the numbers of ED visits, diagnostic procedures, hospital admissions and migraine-related hospitalization days. These long-term benefits of topiramate manifested without any increase in overall headache-related costs. Furthermore, in detailed modelling analyses based on UK and US data, topiramate-induced savings in acute medical services were estimated to offset about one-quarter of the monthly per patient cost of the topiramate regimen, which was shown to be a dominant cost-effective intervention relative to no preventive therapy: cost-effectiveness ratios were calculated as pound 5728 per quality-adjusted life-year (QALY) [2005 costings] and $US10 888 per QALY (2002 costings), respectively. Overall, there is a need to improve quality of care in migraine, and prophylactic therapy appears to be an effective option, particularly with respect to decreasing resource use and improving productivity. For both health-plan payers and employers, topiramate appears to be a cost-effective intervention for preventing migraine.
authors.affiliation: Department of Neurology, Hospital Clínico Universitario, Universidad de Valencia, 46010 Valencia, Spain. jlaineza@meditex.es
authors.forename: Miguel J A
authors.initials: MJ
authors.lastname: Láinez
mesh_terms: D000328:Adult; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D016208:Databases, Factual; D004526:Efficiency; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D000077236:Topiramate; D006113:United Kingdom / Q000453:epidemiology; D014481:United States / Q000453:epidemiology
chemical_list: D000077236:Topiramate; D005632:Fructose
references.citation: J Manag Care Pharm. 2005 Mar;11(2):137-44
references.pmid: 15766320
references.citation: Headache. 2001 Jul-Aug;41(7):638-45
references.pmid: 11554951
references.citation: Clin Ter. 2000 May-Jun;151(3):145-8
references.pmid: 10958046
references.citation: Headache. 2005 Sep;45(8):1012-22
references.pmid: 16109115
references.citation: Headache. 2004 Nov-Dec;44(10):1050-5
references.pmid: 15546274
references.citation: Dis Manag. 2007 Jun;10(3):138-46
references.pmid: 17590144
references.citation: Curr Opin Neurol. 2008 Jun;21(3):309-15
references.pmid: 18451715
references.citation: Neurology. 2000 Sep 26;55(6):754-62
references.pmid: 10993991
references.citation: Headache. 1999 Oct;39(9):633-43
references.pmid: 11284461
references.citation: Neurology. 2008 Apr 22;70(17):1555-63
references.pmid: 18427072
references.citation: Clin Neuropharmacol. 2006 Sep-Oct;29(5):269-75
references.pmid: 16960472
references.citation: Expert Opin Pharmacother. 2007 Nov;8(16):2811-23
references.pmid: 17956201
references.citation: Clin Ther. 2005 Feb;27(2):154-65
references.pmid: 15811478
references.citation: Headache. 2003 Nov-Dec;43(10):1116-8; author reply 1118
references.pmid: 14629251
references.citation: Cochrane Database Syst Rev. 2004;(2):CD003225
references.pmid: 15106196
references.citation: Eur Neurol. 2007;58(4):215-7
references.pmid: 17827966
references.citation: Headache. 2007 Jul-Aug;47(7):1037-49
references.pmid: 17635595
references.citation: Headache. 2007 Apr;47(4):500-10
references.pmid: 17445099
references.citation: Headache. 1989 Jul;29(7):425-7
references.pmid: 2668225
references.citation: Headache. 2002 Nov-Dec;42(10):978-83
references.pmid: 12453029
references.citation: Arch Neurol. 2004 Apr;61(4):490-5
references.pmid: 15096395
references.citation: J Neurol. 2004 Aug;251(8):943-50
references.pmid: 15316798
references.citation: Cephalalgia. 2006 Dec;26(12):1473-82
references.pmid: 17116098
references.citation: Neurol Sci. 2004 Dec;25(5):245-50
references.pmid: 15624081
references.citation: J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1730-2
references.pmid: 16291905
references.citation: Arch Intern Med. 1999 Apr 26;159(8):813-8
references.pmid: 10219926
references.citation: Curr Med Res Opin. 2004 Nov;20(11):1805-14
references.pmid: 15537481
references.citation: Headache. 1998 Feb;38(2):87-96
references.pmid: 9529763
references.citation: Headache. 2001 Feb;41(2):119-28
references.pmid: 11251695
references.citation: Pharmacoeconomics. 1997;11 Suppl 1:1-10
references.pmid: 10168038
references.citation: J Headache Pain. 2007 Oct;8(5):283-8
references.pmid: 17955167
references.citation: Expert Opin Emerg Drugs. 2006 Sep;11(3):419-27
references.pmid: 16939382
references.citation: Cochrane Database Syst Rev. 2004;(3):CD003226
references.pmid: 15266476
references.citation: Headache. 2003 Jun;43(6):621-7
references.pmid: 12786921
references.citation: Dis Manag. 2005 Dec;8(6):382-91
references.pmid: 16351556
references.citation: JAMA. 2006 Apr 19;295(15):1824-30
references.pmid: 16622144
references.citation: Expert Opin Pharmacother. 2007 Dec;8(17):3029-33
references.pmid: 18001261
references.citation: Cephalalgia. 2002 Apr;22(3):209-21
references.pmid: 12047461
references.citation: Arch Neurol. 1997 Sep;54(9):1141-5
references.pmid: 9311358
references.citation: Neurology. 2002 Mar 26;58(6):885-94
references.pmid: 11914403
references.citation: Am J Manag Care. 2005 Jun;11(2 Suppl):S62-7
references.pmid: 16095269
references.citation: Headache. 2006 Oct;46 Suppl 2:S61-8
references.pmid: 17044843
references.citation: Neurology. 2004 Jul 27;63(2):261-9
references.pmid: 15277618
references.citation: Cephalalgia. 1998 Nov;18(9):605-11
references.pmid: 9876883
references.citation: Headache. 2003 Mar;43(3):171-8
references.pmid: 12603635
references.citation: Am Fam Physician. 2002 Dec 1;66(11):2123-30
references.pmid: 12484694
references.citation: Expert Opin Pharmacother. 2007 Aug;8(11):1605-13
references.pmid: 17685879
references.citation: Headache. 2007 Apr;47 Suppl 1:S52-7
references.pmid: 17425710
references.citation: Headache. 2004 Nov-Dec;44(10):1024-8
references.pmid: 15546267
references.citation: J Neurol. 2004 Feb;251 Suppl 1:I8-11
references.pmid: 14991336
references.citation: Am J Health Syst Pharm. 2007 Jul 15;64(14):1483-91
references.pmid: 17617498
references.citation: Cleve Clin J Med. 2006 Sep;73(9):793-4, 797, 800-1 passim
references.pmid: 16970133